Japanese company Eisai has announced that its Alzheimer’s disease treatment developed with Biogen, Leqembi, has been approved by the country’s Ministry of Health, making it the second country after the United States to clear its use. It can now be used in Japan to treat slowing the progression of mild cognitive impairment and mild dementia caused by Alzheimer’s disease.